Skyrizi (risankizumab-rzaa)
Antipsoriatics Intravenous Vial (Ml); Subcutaneous Syringe (Ml)
Last reviewed · Source: First Databank (FDB) drug data
Overview
USES: This medication is used to treat plaque psoriasis and psoriatic arthritis. It is also used to treat certain bowel diseases (Crohn's disease, ulcerative colitis). Risankizumab belongs to a class of drugs known as monoclonal antibodies.
It works by blocking a certain natural protein in your body (interleukin-23) that may cause inflammation and swelling.
Generic name: risankizumab-rzaa
Pronunciation: (RIS-an-KIZ-ue-mab)
Drug class: Antipsoriatics
Therapeutic class: Gastrointestinal Therapy Agents
Reference product & biosimilars
No reference, biosimilar or interchangeable associated with this drug.
Today’s intelligence on Skyrizi
Indications
The following indications are listed for Skyrizi:
- Crohn's Disease
- Moderate To Severe Plaque Psoriasis
- Psoriatic Arthritis
- Ulcerative Colitis
Also known as: Colitis Ulcerativa, Psoriasis Arthropica, Psoriatic Arthropathy, Regional Enteritis, Regional Ileocolitis.
Dosing
No dosing information is available for this tab.
No dosing information is available for this tab.
| Drug label | Dosing type | Instructions |
|---|---|---|
| Skyrizi 150 Mg/Ml Syringe | Maintenance | Inject 150 mg by subcutaneous route every 12 weeks. |
| Skyrizi 600 Mg/10 Ml Vial | Maintenance | Infuse 600 mg over at least 1 hour(s) by intravenous route once. |
No dosing information is available for this tab.
Drug interactions
There is no enhanced messaging for this drug.
Contraindicated Drug Combination: This drug combination is contraindicated and generally should not be dispensed or administered to the same patient.
Selected Immunosuppressive Agents/Live Vaccines; Live Bcg
SEVERITY LEVEL: 1-Contraindicated Drug Combination: This drug combination is contraindicated and generally should not be dispensed or administered to the same patient.
MECHANISM OF ACTION: A variety of disease modifying agents suppress the immune system. Immunocompromised patients may be at increased risk for uninhibited replication after administration of live, attenuated vaccines or intravesicular BCG. Immune response to vaccines may be decreased during periods of immunocompromise.(1)
CLINICAL EFFECTS: The expected serum antibody response may not be obtained and/or the vaccine may result in illness.(1) After instillation of intravesicular BCG, immunosuppression may interfere with local immune response, or increase the severity of mycobacterial infection following inadvertent systemic exposure.(2)
PREDISPOSING FACTORS: Immunosuppressive diseases (e.g. hematologic malignancies, HIV disease), treatments (e.g. radiation) and drugs may all increase the magnitude of immunodeficiency.
PATIENT MANAGEMENT: The Centers for Disease Control(CDC) Advisory Committee on Immunization Practices (ACIP) states that live-virus and live, attenuated vaccines should not be administered to patients who are immunocompromised. The magnitude of immunocompromise and associated risks should be determined by a physician.(1) For patients scheduled to receive chemotherapy, vaccination should ideally precede the initiation of chemotherapy by 14 days. Patients vaccinated while on immunosuppressive therapy or in the 2 weeks prior to starting therapy should be considered unimmunized and should be revaccinated at least 3 months after discontinuation of therapy.(1) Patients who receive anti-B cell therapies should not receive live vaccines for at least 6 months after such therapies due to a prolonged duration of immunosuppression. An exception is the Zoster vaccine, which can be given at least 1 month after receipt of anti-B cell therapies.(1) The US manufacturer of abatacept states live vaccines should not be given during or for up to 3 months after discontinuation of abatacept.(2) The US manufacturer of live BCG for intravesicular treatment of bladder cancer states use is contraindicated in immunosuppressed patients.(3) The US manufacturer of daclizumab states live vaccines are not recommended during and for up to 4 months after discontinuation of treatment.(4) The US manufacturer of guselkumab states that live vaccines should be avoided during treatment with guselkumab.(5) The US manufacturer of inebilizumab-cdon states that live vaccines are not recommended during treatment and after discontinuation until B-cell repletion. Administer all live vaccinations at least 4 weeks prior to initiation of inebilizumab-cdon.(6) The US manufacturer of ocrelizumab states that live vaccines are not recommended during treatment and until B-cell repletion occurs after discontinuation of therapy. Administer all live vaccines at least 4 weeks prior to initiation of ocrelizumab.(7) The US manufacturer of ozanimod states that live vaccines should be avoided during and for up to 3 months after discontinuation of ozanimod.(8) The US manufacturer of siponimod states that live vaccines are not recommended during treatment and for up to 4 weeks after discontinuation of treatment.(9) The US manufacturer of ustekinumab states BCG vaccines should not be given in the year prior to, during, or the year after ustekinumab therapy.(10) The US manufacturer of satralizumab-mwge states that live vaccines are not recommended during treatment and should be administered at least four weeks prior to initiation of satralizumab-mwge.(11) The US manufacturer of ublituximab-xiiy states that live vaccines are not recommended during treatment and until B-cell recovery. Live vaccines should be administered at least 4 weeks prior to initiation of ublituximab-xiiy.(12) The US manufacturer of etrasimod states that live vaccines should be avoided during and for 5 weeks after treatment. Live vaccines should be administered at least 4 weeks prior to initiation of etrasimod.(13) The US manufacturer of emapalumab-lzsg states that live vaccines should not be administered to patients receiving emapalumab-lzsg and for at least 4 weeks after the last dose of emapalumab-lzsg. The safety of immunization with live vaccines during or following emapalumab-lzsg therapy has not been studied.(14) The US manufacturer of sibeprenlimab-szsi states live vaccines should not be given within 30 days prior to initiation or during treatment with sibeprenlimab-szsi.(15)
DISCUSSION: Killed or inactivated vaccines do not pose a danger to immunocompromised patients.(1) Patients with a history of leukemia who are in remission and have not received chemotherapy for at least 3 months are not considered to be immunocompromised.(1)
Severe Interaction: Action is required to reduce the risk of severe adverse interaction.
Igg Antibodies And Derivatives/Efgartigimod-Alfa
SEVERITY LEVEL: 2-Severe Interaction: Action is required to reduce the risk of severe adverse interaction.
MECHANISM OF ACTION: The neonatal Fc receptor (FcRn) prevents catabolism and mediates recycling of IgG and albumin, which leads to their long persistence in the body.(1,2) Efgartigimod-alfa binds to FcRn and may decrease systemic exposure of other ligands of FcRn, like immunoglobulins and IgG-based antibodies.(3)
CLINICAL EFFECTS: The effectiveness of medicines that bind to FcRn may be decreased.(3)
PREDISPOSING FACTORS: None determined.
PATIENT MANAGEMENT: The manufacturer of efgartigimod-alfa states that efgartigimod-alfa should not be combined with long-term use of FcRn-binding medications. If the medication is essential for the patient, efgartigimod-alfa should be discontinued.(3)
DISCUSSION: Clinical drug interaction studies with efgartigimod-alfa have not been performed. Efgartigimod-alfa may decrease concentrations of compounds that bind to the human FcRn.(3)
Igg Antibodies And Derivatives/Nipocalimab-Aahu
SEVERITY LEVEL: 2-Severe Interaction: Action is required to reduce the risk of severe adverse interaction.
MECHANISM OF ACTION: The neonatal Fc receptor (FcRn) prevents catabolism and mediates recycling of IgG and albumin, which leads to their long persistence in the body.(1,2) Nipocalimab-aahu binds to FcRn and may decrease systemic exposure of other ligands of FcRn, like immunoglobulins and IgG-based antibodies.(3)
CLINICAL EFFECTS: The effectiveness of medicines that bind to FcRn may be decreased.(3)
PREDISPOSING FACTORS: None determined.
PATIENT MANAGEMENT: The manufacturer of nipocalimab-aahu states that nipocalimab-aahu should not be combined with long-term use of FcRn-binding medications. If the medication is essential for the patient, nipocalimab-aahu should be discontinued.(3)
DISCUSSION: Clinical drug interaction studies with nipocalimab-aahu have not been performed. Nipocalimab-aahu may decrease concentrations of compounds that bind to the human FcRn.(3)
Moderate Interaction: Assess the risk to the patient and take action as needed.
Igg Antibodies And Derivatives/Rozanolixizumab-Noli
SEVERITY LEVEL: 3-Moderate Interaction: Assess the risk to the patient and take action as needed.
MECHANISM OF ACTION: The neonatal Fc receptor (FcRn) prevents catabolism and mediates recycling of IgG and albumin, which leads to their long persistence in the body.(1,2) Rozanolixizumab-noli binds to FcRn and may decrease systemic exposure of other ligands of FcRn, like immunoglobulins and IgG-based antibodies.(3)
CLINICAL EFFECTS: The effectiveness of medications that bind to FcRn may be decreased.(3)
PREDISPOSING FACTORS: None determined.
PATIENT MANAGEMENT: The manufacturer of rozanolixizumab-noli states that concurrent use with medications that bind to the human neonatal Fc receptor (FcRn) should be closely monitored for reduced effectiveness of these medications. If long-term use of such medications is essential for the patient, consider discontinuing rozanolixizumab-noli and use alternative therapies.(3)
DISCUSSION: Clinical drug interaction studies with rozanolixizumab-noli have not been performed. Rozanolixizumab-noli may decrease concentrations of compounds that bind to the human FcRn.(3)
Contraindications
There is no enhanced messaging for this drug.
- Active tuberculosis
- Disease of liver
- Inactive tuberculosis
- Severe infection
There are no moderate contraindications for this drug.
Adverse reactions
There is no enhanced messaging for this drug.
More Frequent
- Infection
Rare or Very Rare
- Anaphylaxis
- Cellulitis
- Herpes zoster
- Hyperbilirubinemia
- Hypersensitivity drug reaction
- Increased alanine transaminase
- Increased alkaline phosphatase
- Osteomyelitis
- Pneumonia
- Sepsis
More Frequent
- Acute abdominal pain
- Anemia
- Arthralgia
- Back pain
- Dermatophytosis
- Fatigue
- Fever
- Headache disorder
- Injection site sequelae
- Upper respiratory infection
Less Frequent
- Hypercholesterolemia
- Skin rash
- Urinary tract infection
Rare or Very Rare
- Allergic rhinitis
- Eczema
- Facial edema
- Folliculitis
- Urticaria
Precautions
No enhanced messaging available.
No enhanced messaging available.
No enhanced messaging available.
No enhanced messaging available.
No enhanced messaging available.
ICD codes
| Code | Type | Description |
|---|---|---|
| Crohn's disease | ||
| K50 | ICD10CM | Crohn's disease [regional enteritis] |
| K50.0 | ICD10CM | Crohn's disease of small intestine |
| K50.00 | ICD10CM | Crohn's disease of small intestine without complications |
| K50.01 | ICD10CM | Crohn's disease of small intestine with complications |
| K50.011 | ICD10CM | Crohn's disease of small intestine with rectal bleeding |
| K50.012 | ICD10CM | Crohn's disease of small intestine with intestinal obstruction |
| K50.013 | ICD10CM | Crohn's disease of small intestine with fistula |
| K50.014 | ICD10CM | Crohn's disease of small intestine with abscess |
| K50.018 | ICD10CM | Crohn's disease of small intestine with other complication |
| K50.019 | ICD10CM | Crohn's disease of small intestine with unspecified complications |
| K50.1 | ICD10CM | Crohn's disease of large intestine |
| K50.10 | ICD10CM | Crohn's disease of large intestine without complications |
| K50.11 | ICD10CM | Crohn's disease of large intestine with complications |
| K50.111 | ICD10CM | Crohn's disease of large intestine with rectal bleeding |
| K50.112 | ICD10CM | Crohn's disease of large intestine with intestinal obstruction |
| K50.113 | ICD10CM | Crohn's disease of large intestine with fistula |
| K50.114 | ICD10CM | Crohn's disease of large intestine with abscess |
| K50.118 | ICD10CM | Crohn's disease of large intestine with other complication |
| K50.119 | ICD10CM | Crohn's disease of large intestine with unspecified complications |
| K50.8 | ICD10CM | Crohn's disease of both small and large intestine |
| K50.80 | ICD10CM | Crohn's disease of both small and large intestine without complications |
| K50.81 | ICD10CM | Crohn's disease of both small and large intestine with complications |
| K50.811 | ICD10CM | Crohn's disease of both small and large intestine with rectal bleeding |
| K50.812 | ICD10CM | Crohn's disease of both small and large intestine with intestinal obstruction |
| K50.813 | ICD10CM | Crohn's disease of both small and large intestine with fistula |
| K50.814 | ICD10CM | Crohn's disease of both small and large intestine with abscess |
| K50.818 | ICD10CM | Crohn's disease of both small and large intestine with other complication |
| K50.819 | ICD10CM | Crohn's disease of both small and large intestine with unspecified complications |
| K50.9 | ICD10CM | Crohn's disease, unspecified |
| K50.90 | ICD10CM | Crohn's disease, unspecified, without complications |
| K50.91 | ICD10CM | Crohn's disease, unspecified, with complications |
| K50.911 | ICD10CM | Crohn's disease, unspecified, with rectal bleeding |
| K50.912 | ICD10CM | Crohn's disease, unspecified, with intestinal obstruction |
| K50.913 | ICD10CM | Crohn's disease, unspecified, with fistula |
| K50.914 | ICD10CM | Crohn's disease, unspecified, with abscess |
| K50.918 | ICD10CM | Crohn's disease, unspecified, with other complication |
| K50.919 | ICD10CM | Crohn's disease, unspecified, with unspecified complications |
| Moderate to severe plaque psoriasis | ||
| L40.0 | ICD10CM | Psoriasis vulgaris |
| L40.8 | ICD10CM | Other psoriasis |
| L40.9 | ICD10CM | Psoriasis, unspecified |
| Psoriatic arthritis | ||
| L40.5 | ICD10CM | Arthropathic psoriasis |
| L40.50 | ICD10CM | Arthropathic psoriasis, unspecified |
| L40.51 | ICD10CM | Distal interphalangeal psoriatic arthropathy |
| L40.52 | ICD10CM | Psoriatic arthritis mutilans |
| L40.53 | ICD10CM | Psoriatic spondylitis |
| L40.54 | ICD10CM | Psoriatic juvenile arthropathy |
| L40.59 | ICD10CM | Other psoriatic arthropathy |
| Ulcerative colitis | ||
| K51 | ICD10CM | Ulcerative colitis |
| K51.0 | ICD10CM | Ulcerative (chronic) pancolitis |
| K51.00 | ICD10CM | Ulcerative (chronic) pancolitis without complications |
| K51.01 | ICD10CM | Ulcerative (chronic) pancolitis with complications |
| K51.011 | ICD10CM | Ulcerative (chronic) pancolitis with rectal bleeding |
| K51.012 | ICD10CM | Ulcerative (chronic) pancolitis with intestinal obstruction |
| K51.013 | ICD10CM | Ulcerative (chronic) pancolitis with fistula |
| K51.014 | ICD10CM | Ulcerative (chronic) pancolitis with abscess |
| K51.018 | ICD10CM | Ulcerative (chronic) pancolitis with other complication |
| K51.019 | ICD10CM | Ulcerative (chronic) pancolitis with unspecified complications |
| K51.2 | ICD10CM | Ulcerative (chronic) proctitis |
| K51.20 | ICD10CM | Ulcerative (chronic) proctitis without complications |
| K51.21 | ICD10CM | Ulcerative (chronic) proctitis with complications |
| K51.211 | ICD10CM | Ulcerative (chronic) proctitis with rectal bleeding |
| K51.212 | ICD10CM | Ulcerative (chronic) proctitis with intestinal obstruction |
| K51.213 | ICD10CM | Ulcerative (chronic) proctitis with fistula |
| K51.214 | ICD10CM | Ulcerative (chronic) proctitis with abscess |
| K51.218 | ICD10CM | Ulcerative (chronic) proctitis with other complication |
| K51.219 | ICD10CM | Ulcerative (chronic) proctitis with unspecified complications |
| K51.3 | ICD10CM | Ulcerative (chronic) rectosigmoiditis |
| K51.30 | ICD10CM | Ulcerative (chronic) rectosigmoiditis without complications |
| K51.31 | ICD10CM | Ulcerative (chronic) rectosigmoiditis with complications |
| K51.311 | ICD10CM | Ulcerative (chronic) rectosigmoiditis with rectal bleeding |
| K51.312 | ICD10CM | Ulcerative (chronic) rectosigmoiditis with intestinal obstruction |
| K51.313 | ICD10CM | Ulcerative (chronic) rectosigmoiditis with fistula |
| K51.314 | ICD10CM | Ulcerative (chronic) rectosigmoiditis with abscess |
| K51.318 | ICD10CM | Ulcerative (chronic) rectosigmoiditis with other complication |
| K51.319 | ICD10CM | Ulcerative (chronic) rectosigmoiditis with unspecified complications |
| K51.5 | ICD10CM | Left sided colitis |
| K51.50 | ICD10CM | Left sided colitis without complications |
| K51.51 | ICD10CM | Left sided colitis with complications |
| K51.511 | ICD10CM | Left sided colitis with rectal bleeding |
| K51.512 | ICD10CM | Left sided colitis with intestinal obstruction |
| K51.513 | ICD10CM | Left sided colitis with fistula |
| K51.514 | ICD10CM | Left sided colitis with abscess |
| K51.518 | ICD10CM | Left sided colitis with other complication |
| K51.519 | ICD10CM | Left sided colitis with unspecified complications |
| K51.8 | ICD10CM | Other ulcerative colitis |
| K51.80 | ICD10CM | Other ulcerative colitis without complications |
| K51.81 | ICD10CM | Other ulcerative colitis with complications |
| K51.811 | ICD10CM | Other ulcerative colitis with rectal bleeding |
| K51.812 | ICD10CM | Other ulcerative colitis with intestinal obstruction |
| K51.813 | ICD10CM | Other ulcerative colitis with fistula |
| K51.814 | ICD10CM | Other ulcerative colitis with abscess |
| K51.818 | ICD10CM | Other ulcerative colitis with other complication |
| K51.819 | ICD10CM | Other ulcerative colitis with unspecified complications |
| K51.9 | ICD10CM | Ulcerative colitis, unspecified |
| K51.90 | ICD10CM | Ulcerative colitis, unspecified, without complications |
| K51.91 | ICD10CM | Ulcerative colitis, unspecified, with complications |
| K51.911 | ICD10CM | Ulcerative colitis, unspecified with rectal bleeding |
| K51.912 | ICD10CM | Ulcerative colitis, unspecified with intestinal obstruction |
| K51.913 | ICD10CM | Ulcerative colitis, unspecified with fistula |
| K51.914 | ICD10CM | Ulcerative colitis, unspecified with abscess |
| K51.918 | ICD10CM | Ulcerative colitis, unspecified with other complication |
| K51.919 | ICD10CM | Ulcerative colitis, unspecified with unspecified complications |
ICD code information from First Databank (FDB).
Formulary status
Search health-plan coverage for this drug by ZIP code.
Choose the first character of a health plan name.
Last reviewed · Source: First Databank (FDB) drug data
On this page
Actions
Sign in to save favorites
Saving this drug requires a free Physicians Office Resource account.